TLPH vs. ALRN, CKPT, ANVS, BTAI, VHAQ, MNOV, BLRX, LTRN, AFMD, and RLYB
Should you be buying Talphera stock or one of its competitors? The main competitors of Talphera include Aileron Therapeutics (ALRN), Checkpoint Therapeutics (CKPT), Annovis Bio (ANVS), BioXcel Therapeutics (BTAI), Viveon Health Acquisition (VHAQ), MediciNova (MNOV), BioLineRx (BLRX), Lantern Pharma (LTRN), Affimed (AFMD), and Rallybio (RLYB). These companies are all part of the "pharmaceutical preparations" industry.
Aileron Therapeutics (NASDAQ:ALRN) and Talphera (NASDAQ:TLPH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership, community ranking and analyst recommendations.
In the previous week, Aileron Therapeutics had 5 more articles in the media than Talphera. MarketBeat recorded 7 mentions for Aileron Therapeutics and 2 mentions for Talphera. Aileron Therapeutics' average media sentiment score of 1.44 beat Talphera's score of 0.85 indicating that Talphera is being referred to more favorably in the news media.
Aileron Therapeutics presently has a consensus price target of $19.00, indicating a potential upside of 493.75%. Talphera has a consensus price target of $4.50, indicating a potential upside of 336.89%. Given Talphera's stronger consensus rating and higher possible upside, equities research analysts clearly believe Aileron Therapeutics is more favorable than Talphera.
Aileron Therapeutics received 209 more outperform votes than Talphera when rated by MarketBeat users. However, 100.00% of users gave Talphera an outperform vote while only 66.98% of users gave Aileron Therapeutics an outperform vote.
Aileron Therapeutics has higher earnings, but lower revenue than Talphera. Talphera is trading at a lower price-to-earnings ratio than Aileron Therapeutics, indicating that it is currently the more affordable of the two stocks.
Talphera's return on equity of -95.55% beat Aileron Therapeutics' return on equity.
Aileron Therapeutics has a beta of 2.32, suggesting that its share price is 132% more volatile than the S&P 500. Comparatively, Talphera has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500.
90.9% of Aileron Therapeutics shares are owned by institutional investors. Comparatively, 37.7% of Talphera shares are owned by institutional investors. 5.6% of Aileron Therapeutics shares are owned by insiders. Comparatively, 3.0% of Talphera shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Aileron Therapeutics beats Talphera on 12 of the 17 factors compared between the two stocks.
Get Talphera News Delivered to You Automatically
Sign up to receive the latest news and ratings for TLPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TLPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Talphera Competitors List
Related Companies and Tools
